Support from this grant led to our prior successful discovery and development of the triterpene bevirimat, which is currently in Phase IIb clinical trials. Encouraged by this success, the objectives of the proposed research remain to continuously discover and develop novel anti-HIV clinical trials candidates (other than bevirimat) from plant-derived natural products and their analogs. The following specific studies will be carried out to accomplish our objectives: 1. To discover new leads from natural products. We will identify potent anti-HIV principles from extracts of more than 60 previously unexplored plant species 2. To optimize already identified leads (different from bevirimat). We will focus on synthesizing new water-soluble DCP (chromone) and gomisin G (lignan) analogs, with a goal of enhancing biological profiles, such as overcoming cross-resistance and increasing potency. These two compound classes are chosen for further development, because they are nanomolar HIV-1 inhibitors with unique structures and novel mechanisms of action. 3. To further determine anti-HIV-1 activity and mechanism of action for new and promising candidates. We will conduct both HIV drug screening and mechanistic assays, respectively. The main objectives are to identify novel compounds with potent anti-HIV-1 activity and novel mechanisms of action, including families of compounds with activity against HIV isolates resistant to currently approved drugs. Our strategies are expected to identify the drug targets as well as compounds with novel mechanism of action. A distinctive and valuable collaboration between two academic institutions [Dr. K.H. Lee, Natural Products Research Laboratories (NPRL), UNC and Dr. C.H. Chen, Duke University] has been established and is ongoing to discover and develop novel small molecule HIV inhibitors from natural products and their synthetic analogs. The NPRL has expertise in the bioactivity-directed fractionation and isolation (BDFI) and characterization of bioactive natural products coupled with structural modification of the new leads to optimize their pharmaceutical profiles. Dr. Chen's laboratory at Duke University has the needed expertise, experience, and resources to perform initial activity screening, as well as further mechanistic and pharmacological studies to develop the natural product-based inhibitors through preclinical studies. The long term goal is to identify potent HIV inhibitors with novel structures and mechanisms of action to augment the arsenal of approved HIV drugs. The development of the most promising new leads for clinical trials will be accomplished through licensing the technology to a pharmaceutical company, like Panacos Pharmaceuticals or others, as we did before for the development of bevirimat into clinical trials.

Public Health Relevance

New AIDS drugs are continually needed, particularly as HIV strains resistant to different current anti- retroviral therapies continue to emerge. With one compound already in Phase IIb clinical trials from its anti-HIV research program, the NPRL will be able to successfully discover and develop new anti-HIV drug candidates from novel active constituents of medicinal plants and their synthetic analogs.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
AIDS Discovery and Development of Therapeutics Study Section (ADDT)
Program Officer
Nasr, Mohamed E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Schools of Pharmacy
Chapel Hill
United States
Zip Code
Liu, Qingbo; Li, Wei; Huang, Li et al. (2018) Identification, structural modification, and dichotomous effects on human immunodeficiency virus type 1 (HIV-1) replication of ingenane esters from Euphorbia kansui. Eur J Med Chem 156:618-627
Tian, Ye; Liu, Zhaoqiang; Liu, Jinghan et al. (2018) Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. Eur J Med Chem 151:339-350
Huang, Li; Lai, Wei-Hong; Zhu, Lei et al. (2018) Elimination of HIV-1 Latently Infected Cells by Gnidimacrin and a Selective HDAC Inhibitor. ACS Med Chem Lett 9:268-273
Wei, Lei; Wang, Hui-Ling; Huang, Li et al. (2017) Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus. Bioorg Med Chem Lett 27:2788-2792
Zhao, Yu; Gu, Qiong; Morris-Natschke, Susan L et al. (2016) Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1. J Med Chem 59:9262-9268
Jiang, Cheng; Luo, Pan; Zhao, Yu et al. (2016) Carolignans from the Aerial Parts of Euphorbia sikkimensis and Their Anti-HIV Activity. J Nat Prod 79:578-83
Li, Jizhen; Goto, Masuo; Yang, Xiaoming et al. (2016) Fluorinated betulinic acid derivatives and evaluation of their anti-HIV activity. Bioorg Med Chem Lett 26:68-71
Dang, Zhao; Zhu, Lei; Lai, Weihong et al. (2016) Aloperine and Its Derivatives as a New Class of HIV-1 Entry Inhibitors. ACS Med Chem Lett 7:240-4
Liu, Na; Wei, Lei; Huang, Li et al. (2016) Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus. J Med Chem 59:3689-704
Yan, Min; Lu, Yan; Chen, Chin-Ho et al. (2015) Stelleralides D-J and Anti-HIV Daphnane Diterpenes from Stellera chamaejasme. J Nat Prod 78:2712-8

Showing the most recent 10 out of 119 publications